Therefore, targeting highly abundant immunosuppressive cytokines such as IL-10 and TGF-β in the tumor microenvironment significantly helps to reverse immunosuppression, improving the efficacy of conventional cancer therapies, activating antitumor immunity, and controlling tumorigenesis. The gene discussed is IL10; the disease is neoplasm.